



**Supplemental Figure 1. Summary data of Spike-specific IgG memory B cell frequency prior to (V2) and 14 days after (V4) the booster dose in group A and B subjects.** Those who had two and three prior MVC-COV191 belonged to group A and B, respectively. WT, wild type. MBC, memory B cell



### Group A Spike-specific IgG MBC




### Group B Spike-specific IgG MBC




**Supplemental Figure 2. Comparison of Spike-specific IgG MBC frequencies among subgroups in group A and B subjects.** There are three subgroups, i.e., booster dose with MVC-COV1901 containing Wuhan wild type Spike, booster dose with MVC-COV1901 containing Beta variant Spike 15 µg, and booster dose with MVC-COV1901 containing Beta variant Spike 25 µg, for each of group A and B. One-way ANOVA was used to compare the difference among subgroups. ns, not significant. V2, the vaccination day; V4, 14 days after the booster dose.


### Group A



### Group B



**Supplemental Figure 3. Relationship of Spike-specific IgG MBC frequency and serological neutralization titer with authentic wild type and Beta variant viruses among group A and B subjects.** Linear regression was used to model the relationship between two variables. WT, wild type; NT, neutralization test. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.0001$ .



**Supplemental Figure 4. Cytokine production induced by MVC-**COV1901 or MVC-**COV1901-Beta boosters.****** PBMC samples were stimulated with peptide pools derived from the ancestral Wuhan (WT) or Beta variant spike protein of SARS-CoV-2. The results are shown in mean spot forming units (SFU) per million of PBMCs with error bars representing standard deviations.